BPC-157 activates the EGR-1 and NAB2 feedback regulatory loop, essentially flipping genetic switches that initiate self-sustaining repair programs
This could lead to increased cellular damage and accelerate the aging process, affecting the skin, organs, and overall health
The FDA has classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding, such as immunogenicity, impurities, and insufficient safety evidence for suggested administration routes
Available in BC2 (2mg 10 vials), BC5 (5mg 10 vials), and BC10 (10mg 10 vials), this product offers flexibility for both small-scale assays and extended experimental protocols
Activation of the NLRP3 inflammasome increased ROS generation with a loss of mitochondrial membrane potential and mitochondrial integrity in human microglial cells, independent of virus replication